HIV/AIDS Basics & Prevention

Just Diagnosed

HIV Treatment

Living With HIV

AIDS Policy & Activism

HIV Around the World

Conference Coverage

Atripla (Efavirenz/Tenofovir/FTC)

The Basics | News | Research

Brand Name:	Atripla
Generic Name:	Efavirenz/ tenofovir/ emtricitabine, EFV/TDF/FTC
Adult Single Dose:	One tablet containing 600 mg efavirenz, 300 mg tenofovir and 200 mg FTC
Food & Liquid Restrictions:	Take on an empty stomach
Drug Class:	1 NNRTI + 2 NRTIs

The Basics

FAQs About Atripla (Efavirenz/Tenofovir/FTC) From The Body's "Ask the Experts" Forums (Regularly Updated)
From The Body's "Ask the Experts" Forums
Overview of Atripla (Efavirenz/Tenofovir/FTC) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health
Atripla (Efavirenz + Emtricitabine + Tenofovir) (August 22, 2009)
To read PDF, click here
From AIDS InfoNet
Atripla (March/April 2009)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
Atripla (Efavirenz/Tenofovir/FTC) Patient Product Information (PDF) (September 2008)
From Bristol-Myers Squibb Company and Gilead Sciences, Inc.
Patient Information About Atripla (Efavirenz/Tenofovir/FTC) (PDF) (September 2008)
From Bristol-Myers Squibb Company and Gilead Sciences, Inc.
Atripla (Sustiva + Viread + Emtriva) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
Approval of Atripla (July 12, 2006)
From U.S. Food and Drug Administration

News

Approval for Once-A-Day HIV Pill (December 17, 2007)
In BBC News Online, from BBC News
FDA Approves Gilead, Bristol-Myers Squibb Once-a-Day Combination Antiretroviral Pill (July 13, 2006)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Single-Pill, Once-Daily HIV Drug Regimen Submitted for FDA Approval (April 28, 2006)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Data Supports Bioequivalence for Once-Daily, Single-Pill, Fixed-Dose Combination of Sustiva and Truvada, Drug Companies Announce (January 9, 2006)
Filing of a new drug application is expected in the second quarter of 2006.
To read PDF, click here
From Bristol-Myers Squibb Company and Gilead Sciences, Inc.
Gilead's Fixed-Dose Combination of Truvada + Efavirenz Not Yet Bioequivalent to Drugs Alone (August 10, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation

Research

Study Shows People Can Safely Switch to Atripla (December 2008)
To read PDF, click here
From Project Inform

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.